Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung Cancer
Objective: The standard therapy after failure of the initial non-first line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment in advanced non-small cell lung cancer (NSCLC) has not yet been established. The aim of the current study was to identify whether the 2 TKI trea...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
China Anti-Cancer Association
2012-03-01
|
| Series: | Cancer Biology & Medicine |
| Subjects: | |
| Online Access: | http://www.cancerbiomed.org/index.php/cocr/article/view/7/581 |
| _version_ | 1818157455006236672 |
|---|---|
| author | Fang Wang Gui-fang Guo Hui-juan Qiu Wen-zhuo He Fei-fei Zhou Xu-xian Chen Pi-li Hu |
| author_facet | Fang Wang Gui-fang Guo Hui-juan Qiu Wen-zhuo He Fei-fei Zhou Xu-xian Chen Pi-li Hu |
| author_sort | Fang Wang |
| collection | DOAJ |
| description | Objective: The standard therapy after failure of the initial non-first line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment in advanced non-small cell lung cancer (NSCLC) has not yet been established. The aim of the current study was to identify whether the 2 TKI treatment or chemotherapy (paclitaxel-containing or non-paclitaxel regimen) is the appropriate treatment for patients with NSCLC based on the efficacy of the initial TKIs. Methods: Seventy-two advanced NSCLC patients who had accepted 2nd TKIs or chemotherapy immediately after failure of the initial TKIs in non-first line setting from May 1, 2004 to January 31, 2010 at the Sun Yat-sen University Cancer Center were enrolled. The primary endpoint [2nd progression-free survival (PFS)] and the second endpoint [overall survival (OS)] were compared among the 2nd TKI and chemotherapy groups as well as their subgroups. Results: (1) Twenty-one patients were treated with 2nd TKIs, and 51 patients were administered chemotherapy after failure of the initial non-first line TKI treatment. There was nonsignificant difference in the responses (P=0.900) [2nd PFS (P=0.833) and OS (P=0.369)] between the 2nd TKI and chemotherapy groups. (2) In the 2nd TKI group, 9 patients exhibited PFS≥7 months. The initial TKI treatment group exhibited a longer 2nd PFS than the other 12 patients with an initial PFS<7 months (7 months vs. 2 months, P=0.019). However, these groups had nonsignificantly different OS (P=0.369). (3) In the chemotherapy group, patients with PFS<5 months exhibited longer 2 PFS than those with PFS ≥ 5 months in the initial TKI treatment (3 months vs. 2 months, P=0.039). (4) In the chemotherapy group, patients treated with paclitaxel-containing regimen showed longer 2nd PFS than those treated with non-paclitaxel regimen (5 months vs. 2.3 months, P=0.043). Conclusions: Patients with PFS≥7 months or <5 months under the initial TKI treatment potentially benefit from the 2nd TKI treatment or chemotherapy immediately after failure of the non-first line TKIs. The paclitaxel-containing regimen may improve the 2nd PFS. However, more patient samples are urgently needed to validate these findings. |
| first_indexed | 2024-12-11T15:14:28Z |
| format | Article |
| id | doaj.art-02d2c0c5b95c47d38674413710efd531 |
| institution | Directory Open Access Journal |
| issn | 2095-3941 |
| language | English |
| last_indexed | 2024-12-11T15:14:28Z |
| publishDate | 2012-03-01 |
| publisher | China Anti-Cancer Association |
| record_format | Article |
| series | Cancer Biology & Medicine |
| spelling | doaj.art-02d2c0c5b95c47d38674413710efd5312022-12-22T01:00:37ZengChina Anti-Cancer AssociationCancer Biology & Medicine2095-39412012-03-0191384310.7497/j.issn.2095-3941.2012.01.007Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung CancerFang WangGui-fang GuoHui-juan QiuWen-zhuo HeFei-fei ZhouXu-xian ChenPi-li HuObjective: The standard therapy after failure of the initial non-first line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment in advanced non-small cell lung cancer (NSCLC) has not yet been established. The aim of the current study was to identify whether the 2 TKI treatment or chemotherapy (paclitaxel-containing or non-paclitaxel regimen) is the appropriate treatment for patients with NSCLC based on the efficacy of the initial TKIs. Methods: Seventy-two advanced NSCLC patients who had accepted 2nd TKIs or chemotherapy immediately after failure of the initial TKIs in non-first line setting from May 1, 2004 to January 31, 2010 at the Sun Yat-sen University Cancer Center were enrolled. The primary endpoint [2nd progression-free survival (PFS)] and the second endpoint [overall survival (OS)] were compared among the 2nd TKI and chemotherapy groups as well as their subgroups. Results: (1) Twenty-one patients were treated with 2nd TKIs, and 51 patients were administered chemotherapy after failure of the initial non-first line TKI treatment. There was nonsignificant difference in the responses (P=0.900) [2nd PFS (P=0.833) and OS (P=0.369)] between the 2nd TKI and chemotherapy groups. (2) In the 2nd TKI group, 9 patients exhibited PFS≥7 months. The initial TKI treatment group exhibited a longer 2nd PFS than the other 12 patients with an initial PFS<7 months (7 months vs. 2 months, P=0.019). However, these groups had nonsignificantly different OS (P=0.369). (3) In the chemotherapy group, patients with PFS<5 months exhibited longer 2 PFS than those with PFS ≥ 5 months in the initial TKI treatment (3 months vs. 2 months, P=0.039). (4) In the chemotherapy group, patients treated with paclitaxel-containing regimen showed longer 2nd PFS than those treated with non-paclitaxel regimen (5 months vs. 2.3 months, P=0.043). Conclusions: Patients with PFS≥7 months or <5 months under the initial TKI treatment potentially benefit from the 2nd TKI treatment or chemotherapy immediately after failure of the non-first line TKIs. The paclitaxel-containing regimen may improve the 2nd PFS. However, more patient samples are urgently needed to validate these findings.http://www.cancerbiomed.org/index.php/cocr/article/view/7/581lung neoplasmchemotherapysurvival analysiserlotinib |
| spellingShingle | Fang Wang Gui-fang Guo Hui-juan Qiu Wen-zhuo He Fei-fei Zhou Xu-xian Chen Pi-li Hu Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung Cancer Cancer Biology & Medicine lung neoplasm chemotherapy survival analysis erlotinib |
| title | Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung Cancer |
| title_full | Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung Cancer |
| title_fullStr | Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung Cancer |
| title_full_unstemmed | Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung Cancer |
| title_short | Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung Cancer |
| title_sort | initial progression free survival after non first line tkis therapy potentially guides immediate treatment after its failure in advanced non small cell lung cancer |
| topic | lung neoplasm chemotherapy survival analysis erlotinib |
| url | http://www.cancerbiomed.org/index.php/cocr/article/view/7/581 |
| work_keys_str_mv | AT fangwang initialprogressionfreesurvivalafternonfirstlinetkistherapypotentiallyguidesimmediatetreatmentafteritsfailureinadvancednonsmallcelllungcancer AT guifangguo initialprogressionfreesurvivalafternonfirstlinetkistherapypotentiallyguidesimmediatetreatmentafteritsfailureinadvancednonsmallcelllungcancer AT huijuanqiu initialprogressionfreesurvivalafternonfirstlinetkistherapypotentiallyguidesimmediatetreatmentafteritsfailureinadvancednonsmallcelllungcancer AT wenzhuohe initialprogressionfreesurvivalafternonfirstlinetkistherapypotentiallyguidesimmediatetreatmentafteritsfailureinadvancednonsmallcelllungcancer AT feifeizhou initialprogressionfreesurvivalafternonfirstlinetkistherapypotentiallyguidesimmediatetreatmentafteritsfailureinadvancednonsmallcelllungcancer AT xuxianchen initialprogressionfreesurvivalafternonfirstlinetkistherapypotentiallyguidesimmediatetreatmentafteritsfailureinadvancednonsmallcelllungcancer AT pilihu initialprogressionfreesurvivalafternonfirstlinetkistherapypotentiallyguidesimmediatetreatmentafteritsfailureinadvancednonsmallcelllungcancer |